Pezzoli G, Canesi M, Pesenti A, Mariani C B
Ospedale Maggiore Policlinico, University of Milan, Italy.
J Neural Transm Suppl. 1995;45:203-12.
In the past 15 years, clinical data of over 1,500 patients treated with pergolide mesylate have been published. Pergolide is a dopamine agonist with a potent stimulating effect on D2 and also on D1 receptors. This pharmacodynamic characteristic seems the most effective in increasing the motility in Parkinson's disease. Pergolide has been used almost exclusively as an adjunct to levodopa treatment. Its positive effects seems to be related to its long plasma half life, about 27 hours, and 5-6 hours of clinical activity; it has shown to be effective on all parkinsonian symptoms except for the reduction of postural reflexes, it reduces off periods and compared to bromocriptine, it considerably improves the activities of daily living. Adverse reactions are, for the most part, mild and reversible, they mostly include nausea and gastroenteric disturbances.
在过去15年里，已发表了1500多名接受甲磺酸培高利特治疗患者的临床数据。培高利特是一种多巴胺激动剂，对D2受体以及D1受体具有强效刺激作用。这种药效学特性似乎在增加帕金森病的运动能力方面最为有效。培高利特几乎一直仅用作左旋多巴治疗的辅助药物。其积极作用似乎与其约27小时的长血浆半衰期以及5至6小时的临床活性有关；除了姿势反射减弱外，它对所有帕金森症状均显示有效，可减少“关”期，并且与溴隐亭相比，它能显著改善日常生活活动能力。不良反应大多轻微且可逆，主要包括恶心和胃肠道不适。
